113 related articles for article (PubMed ID: 28987595)
1. Acylated apelin-13 amide analogues exhibit enzyme resistance and prolonged insulin releasing, glucose lowering and anorexic properties.
O'Harte FPM; Parthsarathy V; Hogg C; Flatt PR
Biochem Pharmacol; 2017 Dec; 146():165-173. PubMed ID: 28987595
[TBL] [Abstract][Full Text] [Related]
2. Apelin-13 analogues show potent in vitro and in vivo insulinotropic and glucose lowering actions.
O'Harte FPM; Parthsarathy V; Hogg C; Flatt PR
Peptides; 2018 Feb; 100():219-228. PubMed ID: 29412822
[TBL] [Abstract][Full Text] [Related]
3. Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice.
Parthsarathy V; Hogg C; Flatt PR; O'Harte FPM
Diabetes Obes Metab; 2018 Feb; 20(2):319-327. PubMed ID: 28730728
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with acylated analogues of apelin-13 amide ameliorates diabetes and improves lipid profile of high-fat fed mice.
O'Harte FPM; Parthsarathy V; Hogg C; Flatt PR
PLoS One; 2018; 13(8):e0202350. PubMed ID: 30157220
[TBL] [Abstract][Full Text] [Related]
5. Chronic apelin analogue administration is more effective than established incretin therapies for alleviating metabolic dysfunction in diabetic db/db mice.
O'Harte FPM; Parthsarathy V; Flatt PR
Mol Cell Endocrinol; 2020 Mar; 504():110695. PubMed ID: 31904406
[TBL] [Abstract][Full Text] [Related]
6. Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus.
Lynch AM; Pathak N; Flatt YE; Gault VA; O'Harte FP; Irwin N; Flatt PR
Eur J Pharmacol; 2014 Nov; 743():69-78. PubMed ID: 25246014
[TBL] [Abstract][Full Text] [Related]
7. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
Gault VA; Kerr BD; Harriott P; Flatt PR
Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
[TBL] [Abstract][Full Text] [Related]
8. Beneficial actions of a long-acting apelin analogue in diabetes are related to positive effects on islet cell turnover and transdifferentiation.
Tanday N; Irwin N; Moffett RC; Flatt PR; O'Harte FPM
Diabetes Obes Metab; 2020 Dec; 22(12):2468-2478. PubMed ID: 32844576
[TBL] [Abstract][Full Text] [Related]
9. A novel chemically modified analogue of xenin-25 exhibits improved glucose-lowering and insulin-releasing properties.
Parthsarathy V; Irwin N; Hasib A; Martin CM; McClean S; Bhat VK; Ng MT; Flatt PR; Gault VA
Biochim Biophys Acta; 2016 Apr; 1860(4):757-64. PubMed ID: 26802310
[TBL] [Abstract][Full Text] [Related]
10. Esculentin-2CHa(1-30) and its analogues: stability and mechanisms of insulinotropic action.
Vasu S; McGahon MK; Moffett RC; Curtis TM; Conlon JM; Abdel-Wahab YH; Flatt PR
J Endocrinol; 2017 Mar; 232(3):423-435. PubMed ID: 28115493
[TBL] [Abstract][Full Text] [Related]
11. A novel acylated form of (d-Ala(2))GIP with improved antidiabetic potential, lacking effect on body fat stores.
Martin CM; Irwin N; Flatt PR; Gault VA
Biochim Biophys Acta; 2013 Jun; 1830(6):3407-13. PubMed ID: 23518200
[TBL] [Abstract][Full Text] [Related]
12. Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.
Kerr BD; Irwin N; O'Harte FP; Bailey CJ; Flatt PR; Gault VA
Biochem Pharmacol; 2009 Oct; 78(8):1008-16. PubMed ID: 19523458
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.
Irwin N; Clarke GC; Green BD; Greer B; Harriott P; Gault VA; O'Harte FP; Flatt PR
Biochem Pharmacol; 2006 Sep; 72(6):719-28. PubMed ID: 16859646
[TBL] [Abstract][Full Text] [Related]
14. Effects of lipoic acid on apelin in 3T3-L1 adipocytes and in high-fat fed rats.
Fernández-Galilea M; Pérez-Matute P; Prieto-Hontoria P; Martínez JA; Moreno-Aliaga MJ
J Physiol Biochem; 2011 Sep; 67(3):479-86. PubMed ID: 21461750
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic Islet APJ Deletion Reduces Islet Density and Glucose Tolerance in Mice.
Han S; Englander EW; Gomez GA; Rastellini C; Quertermous T; Kundu RK; Greeley GH
Endocrinology; 2015 Jul; 156(7):2451-60. PubMed ID: 25965959
[TBL] [Abstract][Full Text] [Related]
16. Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16).
Irwin N; Green BD; Parker JC; Gault VA; O'Harte FP; Flatt PR
Regul Pept; 2006 Jul; 135(1-2):45-53. PubMed ID: 16675042
[TBL] [Abstract][Full Text] [Related]
17. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice.
Sörhede Winzell M; Magnusson C; Ahrén B
Regul Pept; 2005 Nov; 131(1-3):12-7. PubMed ID: 15970338
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone induces apelin mRNA expression and secretion in mouse 3T3-L1 adipocytes.
Kralisch S; Lossner U; Bluher M; Paschke R; Stumvoll M; Fasshauer M
Regul Pept; 2007 Mar; 139(1-3):84-9. PubMed ID: 17126924
[TBL] [Abstract][Full Text] [Related]
19. Brevinin-2-related peptide and its [D4K] analogue stimulate insulin release in vitro and improve glucose tolerance in mice fed a high fat diet.
Abdel-Wahab YH; Patterson S; Flatt PR; Conlon JM
Horm Metab Res; 2010 Aug; 42(9):652-6. PubMed ID: 20496306
[TBL] [Abstract][Full Text] [Related]
20. Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice.
Irwin N; Montgomery IA; Moffett RC; Flatt PR
Biochem Pharmacol; 2013 Jan; 85(1):81-91. PubMed ID: 23085436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
